Clinical Trial Search

Primary: Objective Response Rate — 10 percentage of participants

Primary: Change From Baseline in AISRS Total Score at Day 42 — -12.1; -11.7; -12.2 score on a scale — p=0.6026

Primary: Quotient of Stimulated C-peptide/Glucose Level Normalized for IEQ/Kg Infused in Response to MMTT — .000000077; 0.000000079 ng/mg glucose/IEQ/kg

Primary: Mean Percent Weight Change — -4.89; -3.18; -10.11 percent of change

Primary: Percentage of Participants With Grade 3 or 4 Solicited Local Adverse Events (AEs) — 0; 0 percentage of participants

Primary: Number of Subjects With Adverse Events as Assessed by CTCAE 4.03 — 106 Participants

Primary: Percentage of Participants With Overall Response Rate — 34.5; 29 percentage of participants

Primary: Symptomatic Skeletal Event-free Survival (SSE-FS) — 21.1; 19.9 Months — p=0.4843

Primary: Change in Plasma Methamphetamine (METH) Area Under the Curve (AUCinf) Resulting From METH Challenge Doses Following Single IV Doses of IXT-m200 — 1635; 1433; 1265; 1233…

Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale

Primary: Predicted Peak Serum Silver Concentration (Cmax) — 17.8 ng/ml

Primary: Clinical Cure on Day 21 — 34; 37; 6; 5 Participants — p=0.6154

Primary: Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1…

Primary: Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event — 0; 0; 0; 0 Participants

Primary: Best Overall Response Rate — 26 Percentage of participants with response